HK1159659A1 - Treatment of autoimmune disease by modulating annexin-1 (lipocortin 1) -i( i) - Google Patents

Treatment of autoimmune disease by modulating annexin-1 (lipocortin 1) -i( i)

Info

Publication number
HK1159659A1
HK1159659A1 HK12100039.9A HK12100039A HK1159659A1 HK 1159659 A1 HK1159659 A1 HK 1159659A1 HK 12100039 A HK12100039 A HK 12100039A HK 1159659 A1 HK1159659 A1 HK 1159659A1
Authority
HK
Hong Kong
Prior art keywords
lipocortin
treatment
autoimmune disease
annexin
modulating
Prior art date
Application number
HK12100039.9A
Other languages
English (en)
Chinese (zh)
Inventor
Mauro Perretti
Fulvio Dacquisto
Roderick John Flower
Original Assignee
Queen Mary & Westfield College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queen Mary & Westfield College filed Critical Queen Mary & Westfield College
Publication of HK1159659A1 publication Critical patent/HK1159659A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Tropical Medicine & Parasitology (AREA)
HK12100039.9A 2008-12-02 2012-01-04 Treatment of autoimmune disease by modulating annexin-1 (lipocortin 1) -i( i) HK1159659A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0822011.3A GB0822011D0 (en) 2008-12-02 2008-12-02 Treatment
PCT/GB2009/002810 WO2010064012A2 (en) 2008-12-02 2009-12-02 Treatment

Publications (1)

Publication Number Publication Date
HK1159659A1 true HK1159659A1 (en) 2012-08-03

Family

ID=40262550

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12100039.9A HK1159659A1 (en) 2008-12-02 2012-01-04 Treatment of autoimmune disease by modulating annexin-1 (lipocortin 1) -i( i)

Country Status (14)

Country Link
US (3) US8980255B2 (xx)
EP (2) EP2889312B1 (xx)
JP (4) JP2012510507A (xx)
KR (1) KR101792887B1 (xx)
CN (2) CN102272156A (xx)
BR (1) BRPI0917037A2 (xx)
DK (1) DK2384339T3 (xx)
ES (1) ES2535724T3 (xx)
GB (1) GB0822011D0 (xx)
HK (1) HK1159659A1 (xx)
PL (1) PL2384339T3 (xx)
PT (1) PT2384339E (xx)
RU (1) RU2554801C2 (xx)
WO (1) WO2010064012A2 (xx)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100986744B1 (ko) * 2008-07-10 2010-10-08 주식회사 한랩 자동 평형형 원심분리기 및 그 제어 방법
GB0822011D0 (en) 2008-12-02 2009-01-07 Queen Mary & Westfield College Treatment
US9127051B2 (en) * 2010-06-09 2015-09-08 Queen Mary & Westfield College, University Of London Annexin 1 antibody
WO2012031023A2 (en) * 2010-08-31 2012-03-08 The Research Foundation Of State University Of New York Treatment of inflammatory bowel diseases using a tripeptide
GB201121564D0 (en) 2011-12-14 2012-01-25 Queen Mary & Westfield College Use of antibody
KR102065112B1 (ko) 2013-02-28 2020-01-10 삼성전자주식회사 높은 항원 선택성을 갖는 항체의 스크리닝 방법
CN104144091A (zh) * 2013-05-10 2014-11-12 中国电信股份有限公司 家庭网关业务承载实现方法和家庭网关
WO2014197681A1 (en) * 2013-06-05 2014-12-11 Rheumco Llc Treatment of immune, inflammatory and degenerative arthritides with tin-117m
KR20150029457A (ko) 2013-09-10 2015-03-18 삼성전자주식회사 아넥신 a1에 결합하는 폴리펩타이드 및 그의 용도
GB201702091D0 (en) * 2017-02-08 2017-03-22 Medannex Ltd Specific binding molecules
US20210353721A1 (en) * 2018-08-07 2021-11-18 The Brigham And Women's Hospital, Inc. Methods and compositions relating to inhibiting cardiovascular calcification via annexin a1
GB201813137D0 (en) 2018-08-10 2018-09-26 Medannex Ltd Cancer treatment with an antibody
JP7224628B2 (ja) * 2019-02-01 2023-02-20 国立研究開発法人産業技術総合研究所 抗ｍｃ１６抗体
TW202332698A (zh) 2021-11-18 2023-08-16 英商梅德安納克斯有限公司 癌症之組合療法
CN117018185A (zh) * 2022-03-18 2023-11-10 江苏靶标生物医药研究所有限公司 TNF-α纳米抗体与PGE2联用在制备溃疡性结肠炎药物中的应用
CN116183933A (zh) * 2023-02-21 2023-05-30 上海市第一人民医院 生物标志物组合物及其在制备评价机体免疫功能的产品中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5051364A (en) 1989-02-16 1991-09-24 The Salk Institute For Biological Studies Anti-lipocortin-I and anti-lipocortin-II monoclonal antibodies
US5565338A (en) * 1990-06-04 1996-10-15 La Jolla Institute For Allergy And Immunology Suppressor T-cell hybridoma and production of allergen specific glycosylation inhibiting factor
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CN1169735A (zh) * 1994-10-25 1998-01-07 葛兰素集团有限公司 Cd23结合剂
WO2003057715A2 (en) 2001-12-28 2003-07-17 The Regents Of The University Of California Novel ligand involved in the transmigration of leukocytes .
CN1726395A (zh) * 2002-12-17 2006-01-25 北京诺赛基因组研究中心有限公司 胰腺癌的特异标记
US8198020B2 (en) * 2003-08-22 2012-06-12 Potentia Pharmaceuticals, Inc. Compositions and methods for enhancing phagocytosis or phagocyte activity
EP1670510A1 (en) * 2003-09-24 2006-06-21 Peter Krammer Antibodies against annexins, use thereof for therapy and diagnosis. use of annexins for therapy and diagnosis.
UY28886A1 (es) * 2004-05-10 2005-12-30 Boehringer Ingelheim Int Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18
CA2572451C (en) 2004-06-02 2016-05-10 Sidney Kimmel Cancer Center Annexin a1 based vascular targets for detecting, imaging and treating neoplasia or neovasculature
KR20090029703A (ko) * 2006-05-26 2009-03-23 에자이 알앤드디 매니지먼트 가부시키가이샤 이미다조아제피논 화합물
GB0822011D0 (en) 2008-12-02 2009-01-07 Queen Mary & Westfield College Treatment

Also Published As

Publication number Publication date
RU2554801C2 (ru) 2015-06-27
JP6813613B2 (ja) 2021-01-13
KR101792887B1 (ko) 2017-11-01
RU2011120411A (ru) 2013-01-10
US20200157196A1 (en) 2020-05-21
GB0822011D0 (en) 2009-01-07
WO2010064012A3 (en) 2010-07-29
CN102272156A (zh) 2011-12-07
PT2384339E (pt) 2015-05-22
EP2889312B1 (en) 2018-08-29
DK2384339T3 (en) 2015-04-27
US8980255B2 (en) 2015-03-17
KR20110099014A (ko) 2011-09-05
EP2384339A2 (en) 2011-11-09
JP2012510507A (ja) 2012-05-10
US20150239965A1 (en) 2015-08-27
US20120034209A1 (en) 2012-02-09
EP2889312A2 (en) 2015-07-01
JP2019104754A (ja) 2019-06-27
ES2535724T3 (es) 2015-05-14
EP2889312A3 (en) 2015-10-21
EP2384339B1 (en) 2015-01-28
BRPI0917037A2 (pt) 2019-12-17
JP2016153426A (ja) 2016-08-25
WO2010064012A2 (en) 2010-06-10
JP2015134782A (ja) 2015-07-27
PL2384339T3 (pl) 2015-06-30
CN107096023A (zh) 2017-08-29

Similar Documents

Publication Publication Date Title
HK1159659A1 (en) Treatment of autoimmune disease by modulating annexin-1 (lipocortin 1) -i( i)
BR112012002124A2 (pt) tratamento da doença de crohn com laquinimode.
EP2365815A4 (en) EXTRACELLULAR MATRIX COMPOSITIONS FOR THE TREATMENT OF CANCER
IL230335A (en) A drug used to treat cartilage disease
ZA200902374B (en) Compositions useful for the treatment of diabetes
EP2382176A4 (en) USE OF CURCUMIN ANALOGUES CONTAINING NITROGEN FOR THE TREATMENT OF ALZHEIMER'S DISEASE
ZA201203856B (en) Morpholinothiazoles as alpha 7 positive allosteric modulators
EP2137112A4 (en) WATER TREATMENT WITH LOW POTENTIAL
IL198166A0 (en) Electrolytic tissue treatment devices
EP2322109A4 (en) ENDOSCOPE TREATMENT INSTRUMENT
IL226000A0 (en) Accordion capsule containing levodopa for improved treatment of symptoms of Parkinson's disease
HK1159654A1 (en) Novel octapeptide compounds derived from somatostatin and therapeutic use thereof
EP2209458A4 (en) SKIN TREATMENT COMPOSITIONS
ZA201101303B (en) Kit for the treatment of onychomycosis
EP2091480A4 (en) SYSTEM FOR THE TREATMENT OF HEART TISSUE
EP2478853A4 (en) ENDOSCOPE TREATMENT INSTRUMENT
ZA201100165B (en) Use of hdac inhibitors for the treatment of hodgkin's disease
EP2319442A4 (en) TREATMENT INSTRUMENT FOR ENDOSCOPE
IL225755B (en) amido derivatives - 6 of epoxymorphinans - a5, 4 for the treatment of pain
EP2421554A4 (en) TISSUE KALLICREIN FOR THE TREATMENT OF HUNTINGTON'S DISEASE
EP2182976A4 (en) TREATMENT OF AUTOIMMUNE DISEASES
IL226799A0 (en) Proline analogs as ligands for cannabinoid receptors for pain relief
PL2323625T3 (pl) Nowa kompozycja do leczenia pigmentacji wybroczynowych
EP2285818A4 (en) BELOXEPINE, ITS ENANTIOMERS AND ANALOGUE FOR PAIN TREATMENT
BRPI0908376A8 (pt) ciclosporina não imunossupressiva para o tratamento de uma distrofia muscular